“Reverse” Payments Anti-Competitive In K-Dur Pact But Not All Cases – FTC
Executive Summary
The Federal Trade Commission's ruling that the settlement between Schering-Plough and Upsher-Smith relating to K-Dur is anti-competitive stops short of defining all "reverse" payments as illegal
You may also be interested in...
Patent Suit Settlements On The Rise After Failure Of FTC Challenges – Barr
Settlements of patent litigation cases have become increasingly common because the Federal Trade Commission has been unsuccessful in challenging the validity of some agreements, Barr CEO Bruce Downey said Jan. 5 at the Morgan Stanley Pharmaceutical CEOs Unplugged conference in New York
Patent Suit Settlements On The Rise After Failure Of FTC Challenges – Barr
Settlements of patent litigation cases have become increasingly common because the Federal Trade Commission has been unsuccessful in challenging the validity of some agreements, Barr CEO Bruce Downey said Jan. 5 at the Morgan Stanley Pharmaceutical CEOs Unplugged conference in New York
FTC Loses K-Dur Antitrust Case; Failure To Consider Schering Patent Cited
The Federal Trade Commission should consider the potential exclusionary scope of a brand-name drug company's patents when evaluating whether a settlement with a generic company is anticompetitive, a federal appeals court ruled March 8